sur CTT Pharmaceutical Holdings, Inc. (NASDAQ:CTTH)
CTT Pharmaceutical Holdings, Inc. Advances Its Financial and Scientific Development
On December 30, 2025, CTT Pharmaceutical Holdings, Inc. announced a significant development with the filing of a Form S-1 registration statement with the U.S. SEC. This step marks the company's transition to a fully reporting status, underscoring its commitment to regulatory compliance and transparency.
The company has also progressed its Equity Line of Credit from $3 million to $10 million. This financial reinforcement is intended to support the commercialization of CTT's innovative micelle-enhanced thin film oral delivery systems and further scientific advancements.
The recent approval of a peer-reviewed manuscript highlights CTT's scientific strides. The manuscript discusses the future of micelle-enhanced thin film technologies, aiming to enhance the visibility and impact of their scientific pursuits.
CTT is now preparing for manufacturing readiness and compliance with regulatory standards. These foundational efforts reflect its focus on disciplined growth and long-term value.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CTT Pharmaceutical Holdings, Inc.